A detailed history of Jpmorgan Chase & CO transactions in X Biotech Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,694 shares of XBIT stock, worth $60,162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,694
Previous 7,924 9.72%
Holding current value
$60,162
Previous $40,000 67.5%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$5.55 - $7.95 $4,273 - $6,121
770 Added 9.72%
8,694 $67,000
Q2 2024

Aug 12, 2024

BUY
$4.54 - $9.89 $35,802 - $77,992
7,886 Added 20752.63%
7,924 $40,000
Q4 2022

Feb 13, 2023

SELL
$3.03 - $3.79 $33,626 - $42,061
-11,098 Reduced 99.66%
38 $0
Q3 2022

Nov 14, 2022

SELL
$3.58 - $5.88 $13,145 - $21,591
-3,672 Reduced 24.8%
11,136 $40,000
Q2 2022

Aug 11, 2022

SELL
$5.13 - $9.2 $1,462 - $2,622
-285 Reduced 1.89%
14,808 $83,000
Q1 2022

May 11, 2022

BUY
$8.64 - $11.71 $54,950 - $74,475
6,360 Added 72.83%
15,093 $131,000
Q4 2021

Feb 10, 2022

BUY
$10.95 - $16.07 $6,745 - $9,899
616 Added 7.59%
8,733 $98,000
Q3 2021

Nov 12, 2021

BUY
$12.95 - $18.24 $105,115 - $148,054
8,117 New
8,117 $105,000

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $211M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.